Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Enoxaparin Sodium
Therapeutic Area : Hematology
Study Phase : Approved
Sponsor : Sanofi
Deal Size : Undisclosed
Deal Type : Agreement
Sanofi and Minapharm Sign an Exclusive Agreement for Localizing the Manufacture of Clexane®
Details : The agreement aims for the for the localization of the full range of its flagship market leader product, Clexane (enoxaparin sodium), used to prevent clots from getting bigger or stopping new clots from forming.
Brand Name : Clexane
Molecule Type : Small molecule
Upfront Cash : Undisclosed
December 10, 2023
Lead Product(s) : Enoxaparin Sodium
Therapeutic Area : Hematology
Highest Development Status : Approved
Sponsor : Sanofi
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Undisclosed
Therapeutic Area : Immunology
Study Phase : Undisclosed
Sponsor : Bioventure Healthcare
Deal Size : Undisclosed
Deal Type : Agreement
Details : Minapharm Pharmaceuticals and MiGenTra GmbH will share responsibilities in the Territory to file, launch and commercialize Alvotech's portfolio of licensed biosimilars once approved, under Bioventure's exclusive strategic partnership with Alvotech in the...
Brand Name : Undisclosed
Molecule Type : Large molecule
Upfront Cash : Undisclosed
November 30, 2022
Lead Product(s) : Undisclosed
Therapeutic Area : Immunology
Highest Development Status : Undisclosed
Sponsor : Bioventure Healthcare
Deal Size : Undisclosed
Deal Type : Agreement
LOOKING FOR A SUPPLIER?